SEPIAPTERIN INHIBITS ADAPTIVE LEFT VENTRICULAR HYPERTROPHY BUT PREVENTS DILATORY REMODELING INDUCED BY PRESSURE OVERLOAD IN RATS  by Yoshioka, Kei et al.
E214
JACC April 5, 2011
Volume 57, Issue 17
  CARDIAC FUNCTION AND HEART FAILURE 
SEPIAPTERIN INHIBITS ADAPTIVE LEFT VENTRICULAR HYPERTROPHY BUT PREVENTS DILATORY 
REMODELING INDUCED BY PRESSURE OVERLOAD IN RATS
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-11:15 a.m.
Session Title: Stem Cells and Myocardial Metabolism
Abstract Category: 20. Myocardial Function/Heart Failure—Basic/Molecular
Session-Poster Board Number: 1016-51
Authors: Kei Yoshioka, Hajime Otani, Takayuki Shimazu, Masanori Fujita, Toru Okazaki, Daisuke Sato, Toshiji IwasakA, Kansai Medical University, 
Moriguchi, Japan
Background:  Pressure overload induced by transverse aortic constriction (TAC) leads to left ventricular hypertrophy (LVH) and heart failure (HF). 
We investigated whether tetrahydrobiopterin (BH4) precursor, sepiapterin, increases bioavailability of nitric oxide (NO) and prevents LVH and HF in 
rats with TAC.
Methods: TAC was created in rats at 8 weeks after birth. Sepiapterin (10 mg/kg/day) was orally administered immediately after TAC for 8 weeks or 
at 16 weeks after TAC for 8 weeks. Cardiac geometry and function was assessed by echocardiography. Bioavailability of NO and oxidative/nitrosative 
stress were evaluated by nitrate plus nitrite (NOx) generation and nitrotyrosine (NT) formation, respectively. Angiogenesis was evaluated by CD31-
positive endothelial cell (ETC) density.
Results:  Sepiapterin increased myocardial BH4 by 3-fold. When administration of sepiapterin was started at the time of TAC, it increased NOx 
generation and inhibited NT formation. This sepiapterin treatment inhibited concentric LVH 8 weeks after TAC associated with heart failure (HF) as 
demonstrated by an increase in lung weight/body weight. When sepiapterin administration was started 16 weeks after TAC, it reversed cardiomyocyte 
hypertrophy, increased ETC density, and inhibited LV dilatation and HF associated with an increase in NOx generation and inhibition of NT formation. 
A NO synthase inhibitor, L-NAME, cancelled the inhibitory effect of sepiapterin on concentric LVH and the beneficial effect of late sepiapterin 
treatment on cardiomyocyte hypertrophy, ETC density and LV function. A superoxide scavenger, N-2-mercapto-propionyl glycine, inhibited NT 
formation but did not increase NOx generation and ETC density nor did it prevent concentric LVH and subsequent LV dilatation and HF after TAC. 
Conclusions:  Sepiapterin administration at the onset of pressure overload disrupts adaptive response to maintain myocardial function by 
inhibiting concentric LVH, but when administered after established LVH, it prevents dilatory remodeling and HF. This beneficial effect of sepiapterin is 
mediated by NO-dependent inhibition of cardiomyocyte hypertrophy and an increase in angiogenesis.
